News
Liver injury. Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC ...
Hosted on MSN16d
Understanding liver fibrosis: Insights from Alagille syndromeMore information: Jan Mašek et al, Jag1 insufficiency alters liver fibrosis via T cell and hepatocyte differentiation defects, EMBO Molecular Medicine (2024). DOI: 10.1038/s44321-024-00145-8 ...
Changes in certain liver tests are common in patients with Alagille syndrome and PFIC but can worsen during treatment. These changes may be a sign of liver injury. In PFIC, this can be serious or ...
In unusual circumstances, Ipsen has been given the green light for its odevixibat drug for severe itching (pruritus) in patients with rare liver disease Alagille syndrome (ALGS) in the EU – for ...
His breathing became severely compromised due to low oxygen levels caused by advanced liver disease. Hepatopulmonary syndrome (HPS) is a rare and serious condition where liver disease leads to low ...
Learn how nonalcoholic fatty liver disease develops, its warning signs, and the steps to help safeguard the liver.
He was just a day old when he was diagnosed with a genetic disease called Alagille syndrome, a condition that leads to liver failure. Orlando was placed on a transplant list as a baby, and after an ...
It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S. three months of age and older and in Europe for patients two months of age and older.
He was just a day old when he was diagnosed with a genetic disease called Alagille syndrome, a condition that leads to liver failure. Orlando was placed on a transplant list as a baby, and after ...
readings from noninvasive tests commonly have major discrepancies when compared with liver biopsy results, particularly in cases of severe steatosis, according to the results of a new study.
Mirum and Takeda entered into an exclusive license agreement in September 2021 for the development and commercialization of LIVMARLI for rare cholestatic pediatric liver diseases in Japan.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results